Trial Profile
Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer and Other Resectable Cancers; a Window Trial.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Denifanstat (Primary)
- Indications Colon cancer
- Focus Pharmacodynamics
- Acronyms Window
- 18 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 18 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.